A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations

The incidence of HER2 somatic mutations in breast cancer is about 2–4%, mainly occurring in the HR+/HER2- subtype. Preclinical studies suggest that HER2 mutations can lead to constitutive HER2 activation, but effective treatment options for the clinical management of patients with HER2 mutations rem...

Full description

Bibliographic Details
Main Authors: Jing Ma, Xuelu Li, Qianran Zhang, Ning Li, Siwen Sun, Shanshan Zhao, Zuowei Zhao, Man Li
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:Translational Oncology
Subjects:
HER2 mutation
Breast cancer
HER2-targeted therapy
Everolimus
Treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523322001036

Similar Items

Similar Items